Predictive Oncology Subsidiary Helomics Executes Next Phase of Agreement with Interpace to Enhance the Diagnosis of Thyroid Cancer via AI-Driven Models
This phase of the agreement is expected to leverage real world clinical data from Interpace’s two thyroid products, ThyGeNEXT® and ThyraMIR®, coupled with drug response profiles of thyroid tumors from Helomics’ patient-derived tumor profiling platform to build D-CHIP AI-driven models of thyroid cancer. The models will help identify potential druggable targets for treatment of indolent and aggressive thyroid cancers. Ultimately, the companies hope to develop a full pipeline of products that work seamlessly together to both diagnose and assess risk for thyroid cancer in addition to providing appropriate therapy recommendations.
“This phase of our ongoing collaboration with Interpace is a prime example of the capabilities that Helomics can bring to the diagnostic and pharma sectors. This agreement continues to demonstrate the applicability of our smart patient-derived tumor profiling and AI platform to a wide range of cancers and follows recent partnerships in ovarian cancer and prostate cancer,” commented
“The better we understand thyroid cancer, the better equipped we are to both diagnose and predict treatment outcomes,” added
Interpace is a leader in enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications. Interpace’s Diagnostic Business is a fully integrated commercial and bioinformatics business unit that provides clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. Interpace has four commercialized molecular tests and one test in a clinical evaluation process (CEP): PancraGEN® for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; ThyGeNEXT® for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay; ThyraMIR® for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay; and RespriDX® that differentiates lung cancer of primary vs. metastatic origin. In addition, BarreGEN® for Barrett’s Esophagus, is currently in a clinical evaluation program whereby we gather information from physicians using BarreGEN® to assist us in positioning the product for full launch, partnering and potentially supporting reimbursement with payers.
Interpace’s Biopharma Business is a market leader in providing pharmacogenomics testing, genotyping, and biorepository services to the pharmaceutical and biotech industries. The Biopharma Business also advances personalized medicine by partnering with pharmaceutical, academic, and technology leaders to effectively integrate pharmacogenomics into their drug development and clinical trial programs with the goals of delivering safer, more effective drugs to market more quickly, and improving patient care.
For more information, please visit Interpace’s website at www.interpacediagnostics.com.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, relating to the Company's future financial and operating performance. The Companies have attempted to identify forward looking statements by terminology including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company's control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Companies’ actual results to be materially different from those expressed or implied by any forward-looking statement. Additionally, all forward-looking statements are subject to the “Risk Factors” detailed from time to time in the Companies’ most recent Annual Report on Form 10-K and Quarterly Reports on Form 10Q. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Companies undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
Source: Predictive Oncology Inc.